• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾移植后淋巴组织增生性疾病患者的长期随访:肾移植后淋巴组织增生性疾病诱导的手术移植耐受性持续时间、白细胞介素-18病程及再次移植结果

Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation.

作者信息

Birkeland S A, Hamilton-Dutoit S, Bendtzen K

机构信息

Department of Nephrology, Odense University Hospital, Odense, Denmark.

出版信息

Transplantation. 2003 Jul 15;76(1):153-8. doi: 10.1097/01.TP.0000072015.08302.E9.

DOI:10.1097/01.TP.0000072015.08302.E9
PMID:12865802
Abstract

BACKGROUND

Posttransplant lymphoproliferative disorder (PTLD) can be resolved in many transplant patients by the reduction or cessation of immunosuppression, after which many grafts continue to function as the result of a form of operational tolerance. When graft function deteriorates, retransplantation may be an option. Cytokines such as interleukin (IL)-10 and IL-18 may play a role in PTLD tolerance induction and tumor regression. We report long-term follow-up on the duration of graft tolerance and the course of retransplantation in a series of patients who underwent kidney transplantation and demonstrated PTLD, and in whom we were able to perform IL-18 analyses.

RESULTS

Patients were followed for up to 7 years after PTLD diagnosis. Treatment consisted of immunosuppression cessation with radiation therapy in cases with overt monomorphic lymphomas. All patients' PTLDs were resolved, and all patients but one (whose graft was removed) demonstrated a period of operational graft tolerance of up to 5 years. Five patients underwent retransplantation without sign of recurrence of the PTLD up to 3 years after transplantation. In the eight patients analyzed, IL-18 increased significantly during PTLD regression and follow-up in those with long-term operational tolerance.

CONCLUSION

We report on a series of patients with resolved PTLDs demonstrating long-term recurrence-free survival, of whom most experienced a long period of operational graft tolerance. IL-18 seems to play a role in the resolution of the PTLDs. Five patients underwent retransplantation with standard immunosuppression without recurrence. A previous diagnosis of PTLD should not be regarded as a contraindication for later retransplantation.

摘要

背景

许多移植患者的移植后淋巴细胞增生性疾病(PTLD)可通过减少或停用免疫抑制来解决,之后许多移植物因一种操作性耐受形式而继续发挥功能。当移植物功能恶化时,再次移植可能是一种选择。细胞因子如白细胞介素(IL)-10和IL-18可能在PTLD耐受诱导和肿瘤消退中发挥作用。我们报告了一系列接受肾移植并发生PTLD且能够进行IL-18分析的患者移植物耐受持续时间和再次移植过程的长期随访情况。

结果

患者在PTLD诊断后随访长达7年。对于明显的单形性淋巴瘤患者,治疗包括停用免疫抑制并联合放射治疗。所有患者的PTLD均得到缓解,除1例(其移植物被切除)外,所有患者均表现出长达5年的操作性移植物耐受期。5例患者接受了再次移植,移植后3年内无PTLD复发迹象。在分析的8例患者中,IL-18在PTLD消退期间及长期具有操作性耐受的患者随访期间显著升高。

结论

我们报告了一系列PTLD得到缓解且显示长期无复发生存的患者,其中大多数经历了较长时间的操作性移植物耐受。IL-18似乎在PTLD的消退中发挥作用。5例患者在标准免疫抑制下接受再次移植且无复发。既往PTLD诊断不应被视为后期再次移植的禁忌证。

相似文献

1
Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation.肾移植后淋巴组织增生性疾病患者的长期随访:肾移植后淋巴组织增生性疾病诱导的手术移植耐受性持续时间、白细胞介素-18病程及再次移植结果
Transplantation. 2003 Jul 15;76(1):153-8. doi: 10.1097/01.TP.0000072015.08302.E9.
2
Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.初次肾移植后诱导免疫抑制类型与移植后淋巴细胞增生性疾病、移植物存活及患者存活的关联
Transplantation. 2003 Nov 15;76(9):1289-93. doi: 10.1097/01.TP.0000100826.58738.2B.
3
Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses.成人肾移植后淋巴组织增生性疾病:流行病学及登记报告与基于理赔诊断的比较。
Am J Kidney Dis. 2011 Dec;58(6):971-80. doi: 10.1053/j.ajkd.2011.07.015. Epub 2011 Sep 17.
4
Post-transplant lymphoproliferative disorders after live donor renal transplantation.活体供肾肾移植术后移植后淋巴细胞增生性疾病
Clin Transplant. 2005 Oct;19(5):668-73. doi: 10.1111/j.1399-0012.2005.00406.x.
5
Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.移植后淋巴细胞增生性疾病:经临床病理定制治疗后预后改善
Haematologica. 2002 Jan;87(1):67-77.
6
Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?移植后淋巴细胞增生性疾病(PTLD)是由任何特定的免疫抑制药物引起的,还是由移植本身引起的?
Transplantation. 2003 Sep 27;76(6):984-8. doi: 10.1097/01.TP.0000085602.22498.CF.
7
Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.单药利妥昔单抗治疗后对难治性和复发性移植后淋巴细胞增殖性疾病(PTLD)进行挽救性化疗。
Transplantation. 2007 Apr 15;83(7):912-8. doi: 10.1097/01.tp.0000258647.50947.78.
8
Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.既往有移植后淋巴细胞增生性疾病的受者再次肾移植的结果。
Clin Transplant. 2016 Jan;30(1):60-5. doi: 10.1111/ctr.12659.
9
Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation.白细胞介素-10与肾移植后移植后淋巴细胞增殖性疾病
Transplantation. 1999 Mar 27;67(6):876-81. doi: 10.1097/00007890-199903270-00015.
10
Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients.移植后淋巴组织增生性疾病(PTLD)后的肺再次移植:单中心经验及肺移植受者PTLD文献综述
J Heart Lung Transplant. 2005 Jun;24(6):671-9. doi: 10.1016/j.healun.2004.04.011.

引用本文的文献

1
Pre-existing oncohematological disease in kidney transplant recipients: impact on graft survival, acute rejection, and long-term clinical outcomes.肾移植受者既往的肿瘤血液学疾病:对移植肾存活、急性排斥反应及长期临床结局的影响
Front Immunol. 2025 Aug 6;16:1629521. doi: 10.3389/fimmu.2025.1629521. eCollection 2025.
2
Assessment of kidney transplant suitability for patients with prior cancers: is it time for a rethink?评估有既往癌症史患者的肾移植适用性:是否需要重新思考?
Transpl Int. 2019 Dec;32(12):1223-1240. doi: 10.1111/tri.13486. Epub 2019 Aug 28.
3
Post-transplant lymphoproliferative disorder (PTLD) presenting as painful lymphocele 12 years after a cadaveric renal transplant.
尸体肾移植12年后出现疼痛性淋巴囊肿的移植后淋巴细胞增生性疾病(PTLD)
Int Urol Nephrol. 2008;40(2):547-50. doi: 10.1007/s11255-008-9367-2.
4
Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.器官移植受者的免疫抑制治疗与恶性肿瘤:一项系统综述
Drugs. 2007;67(8):1167-98. doi: 10.2165/00003495-200767080-00006.